Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

The structure of liraglutide (a structurally distinct analog of GLP-1RA) was found to be unfavorable for co-formulation with SNAC on account of its stronger membrane-binding properties, which reduced ...

When you take GLP-1 medications, they bind to GLP-1 receptors on your pancreas ... Furthermore, semaglutide was more effective than liraglutide for chronic weight management.

Novo Nordisk’s first GLP-1 drug liraglutide will be off patent in November and in ... ‘In vivo, it is not actually going to bind to albumin, but [the glycan] has sialic acid moieties, which also ...

The lauded Lasker Awards, frequently tied to Nobel Prize acclaim, highlighted the significant accomplishments of three ...

Molecular structure of tirzepatide and the dual activation mechanism of GLP-1 and GIP receptors. AC, Adenylate Cyclase; AKT/PKB, Protein Kinase B; Bcl2, B-cell lymphoma 2; cAMP, Cyclic Adenosine ...

It is currently being investigated in an early Phase 1 clinical trial (NCT02045056) in the U.S. Liraglutide, prescribed for the treatment of diabetes, is an analog of glucagon-like peptide 1 (GLP-1 ..

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...